Zhou, B., Zhang, F., Guo, W., Wang, S., Li, N., Qiu, B., Zhao, L., Li, J., Shao, K., Xue, Q., Lv, F., Gao, S.

Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer

12 de August de 2024 by Zhou, B., Zhang, F., Guo, W., Wang, S., Li, N., Qiu, B., Zhao, L., Li, J., Shao, K., Xue, Q., Lv, F., Gao, S.

Background
Neoadjuvant anti-programmed cell death protein-1 (PD-1) therapy exhibits potential in treating resectable non-small cell lung cancer (NSCLC). Previously, we have reported the 3-year clinical outcomes of this trial, implying the effectivenes…